vs
Side-by-side financial comparison of CIVISTA BANCSHARES, INC. (CIVB) and Cytek Biosciences, Inc. (CTKB). Click either name above to swap in a different company.
Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $47.3M, roughly 1.3× CIVISTA BANCSHARES, INC.). CIVISTA BANCSHARES, INC. runs the higher net margin — 31.7% vs -70.9%, a 102.6% gap on every dollar of revenue. Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 11.3%).
Civista Bancshares, Inc. is a US-based bank holding company operating primarily across the Midwest region. It provides a full suite of personal and commercial banking services including deposit accounts, mortgage, consumer and commercial lending products, as well as wealth management solutions, serving retail consumers, small and medium-sized local businesses and community client segments.
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
CIVB vs CTKB — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.3M | $62.1M |
| Net Profit | $15.0M | $-44.1M |
| Gross Margin | — | 52.9% |
| Operating Margin | — | -9.0% |
| Net Margin | 31.7% | -70.9% |
| Revenue YoY | — | 8.1% |
| Net Profit YoY | 47.4% | -557.1% |
| EPS (diluted) | $0.72 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $47.3M | — | ||
| Q4 25 | $46.3M | $62.1M | ||
| Q3 25 | $44.2M | $52.3M | ||
| Q2 25 | $41.4M | $45.6M | ||
| Q1 25 | $40.6M | $41.5M | ||
| Q4 24 | $40.4M | $57.5M | ||
| Q3 24 | $39.3M | $51.5M | ||
| Q2 24 | $38.1M | $46.6M |
| Q1 26 | $15.0M | — | ||
| Q4 25 | — | $-44.1M | ||
| Q3 25 | $12.8M | $-5.5M | ||
| Q2 25 | $11.0M | $-5.6M | ||
| Q1 25 | $10.2M | $-11.4M | ||
| Q4 24 | — | $9.6M | ||
| Q3 24 | $8.4M | $941.0K | ||
| Q2 24 | $7.1M | $-10.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 52.9% | ||
| Q3 25 | — | 52.7% | ||
| Q2 25 | — | 52.3% | ||
| Q1 25 | — | 48.6% | ||
| Q4 24 | — | 58.5% | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 54.6% |
| Q1 26 | — | — | ||
| Q4 25 | 31.8% | -9.0% | ||
| Q3 25 | 35.4% | -17.6% | ||
| Q2 25 | 31.1% | -23.3% | ||
| Q1 25 | 29.4% | -36.1% | ||
| Q4 24 | 28.2% | 5.2% | ||
| Q3 24 | 25.2% | -8.2% | ||
| Q2 24 | 21.2% | -18.3% |
| Q1 26 | 31.7% | — | ||
| Q4 25 | — | -70.9% | ||
| Q3 25 | 28.9% | -10.5% | ||
| Q2 25 | 26.6% | -12.2% | ||
| Q1 25 | 25.0% | -27.5% | ||
| Q4 24 | — | 16.8% | ||
| Q3 24 | 21.3% | 1.8% | ||
| Q2 24 | 18.5% | -22.4% |
| Q1 26 | $0.72 | — | ||
| Q4 25 | $0.59 | — | ||
| Q3 25 | $0.68 | — | ||
| Q2 25 | $0.71 | — | ||
| Q1 25 | $0.66 | — | ||
| Q4 24 | $0.62 | — | ||
| Q3 24 | $0.53 | — | ||
| Q2 24 | $0.45 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $90.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $553.9M | $341.7M |
| Total Assets | $4.3B | $461.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $90.9M | ||
| Q3 25 | — | $93.3M | ||
| Q2 25 | — | $75.5M | ||
| Q1 25 | — | $95.3M | ||
| Q4 24 | — | $98.7M | ||
| Q3 24 | — | $162.3M | ||
| Q2 24 | — | $177.9M |
| Q1 26 | $553.9M | — | ||
| Q4 25 | $543.5M | $341.7M | ||
| Q3 25 | $499.0M | $378.6M | ||
| Q2 25 | $404.1M | $377.6M | ||
| Q1 25 | $397.4M | $379.6M | ||
| Q4 24 | $388.5M | $395.7M | ||
| Q3 24 | $394.4M | $385.5M | ||
| Q2 24 | $373.8M | $389.1M |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | $461.5M | ||
| Q3 25 | $4.1B | $494.9M | ||
| Q2 25 | $4.2B | $493.3M | ||
| Q1 25 | $4.1B | $482.6M | ||
| Q4 24 | $4.1B | $499.5M | ||
| Q3 24 | $4.1B | $491.2M | ||
| Q2 24 | $4.0B | $483.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-771.0K |
| Free Cash FlowOCF − Capex | — | $-1.8M |
| FCF MarginFCF / Revenue | — | -2.9% |
| Capex IntensityCapex / Revenue | — | 1.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-8.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.3M | $-771.0K | ||
| Q3 25 | $19.0M | $-3.9M | ||
| Q2 25 | $11.1M | $108.0K | ||
| Q1 25 | $3.6M | $-125.0K | ||
| Q4 24 | $48.2M | $2.0M | ||
| Q3 24 | $12.9M | $13.2M | ||
| Q2 24 | $12.2M | $6.2M |
| Q1 26 | — | — | ||
| Q4 25 | $42.1M | $-1.8M | ||
| Q3 25 | — | $-4.6M | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | $3.5M | $-974.0K | ||
| Q4 24 | $44.1M | $1.1M | ||
| Q3 24 | — | $12.2M | ||
| Q2 24 | — | $5.2M |
| Q1 26 | — | — | ||
| Q4 25 | 90.9% | -2.9% | ||
| Q3 25 | — | -8.7% | ||
| Q2 25 | — | -3.2% | ||
| Q1 25 | 8.5% | -2.3% | ||
| Q4 24 | 109.1% | 1.9% | ||
| Q3 24 | — | 23.7% | ||
| Q2 24 | — | 11.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.5% | 1.6% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | 0.4% | 2.0% | ||
| Q4 24 | 10.4% | 1.6% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 2.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.49× | — | ||
| Q2 25 | 1.01× | — | ||
| Q1 25 | 0.36× | — | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | 1.54× | 14.05× | ||
| Q2 24 | 1.73× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CIVB
| Net Interest Income | $37.8M | 80% |
| Noninterest Income | $9.4M | 20% |
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
